---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-24-025793"
form_type: "8-K"
ticker: "ABVC"
cik: "0001173313"
company_name: "ABVC BIOPHARMA, INC."
filed_at: "2024-03-26T23:59:59+00:00"
generated_at: "2026-06-04T07:37:00.722429+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# ABVC enters global licensing deal for Vitargus; potential total fees of $33.5M plus royalties up to $60M

## Summary
- 20-year exclusive global license with ForSeeCon Eye Corp for ophthalmology pipeline including Vitargus.
- ABVC and co-development partner BioFirst each to receive $30M upfront (cash or 5M shares of FEYE at $6/share) within 30 days.
- Additional $3.5M cash milestone per party after next fundraise; 5% royalty on net sales capped at $60M per entity.
- Vitargus valued at $187M by third-party valuer; ABVC retains R&D role for ophthalmic products.
- License covers clinical trial, registration, manufacturing, supply, and distribution rights.

## SEC filing metadata
- accession: 0001213900-24-025793
- form_type: 8-K
- ticker: ABVC
- cik: 0001173313
- company_name: ABVC BIOPHARMA, INC.
- filed_at: 2024-03-26T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1173313/000121390024025793/0001213900-24-025793-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1173313/000121390024025793/ea0202575-8k_abvcbio.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-24-025793
- JSON: https://secwatch.observer/filing/0001213900-24-025793.json
- Plain text: https://secwatch.observer/filing/0001213900-24-025793.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.